What's New

What's New!

We will be regularly updating the latest biomedical literature from MEDLINE, life science journals and onlink books on our site.

--- For December, 2011 ---

1.)

Franke K, Paustenbach D.

Inhal Toxicol. 2011 Dec;23 Suppl 3:1-20.

PMID: 22200078 [PubMed - in process]

2.)

Nakas A, von Meyenfeldt E, Lau K, Muller S, Waller D.

--- For November, 2011 ---

1.)	PET-CT in the diagnosis of localized malignant pleural mesothelioma Clinical Imaging. 2011 Nov; 35(6): 476-7. Dimarakis, I., Rehman, S., Machaal, A., and Shah, R.

2.)	Clinical implications of 18F- fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma Oncology Reports. 2011 Oct 24. doi: 10.3892/or.2011.1520. Abe, Y., Tamura, K., Sakata, I., Ishida, J., Ozeki, Y., Tamura, A., Uematsu, K., Sakai, H., Goya, T., Kanazawa, M., and Machida, K.

3.)	An electronic nose distinguisges exhaled breath of patients with Malignant Pleural Mesothelioma from controls Lung Cancer. 2011 Sep 14. Dragonieri, S., van der Schee, MP, Massaro, T., Schiavulli, N., Brinkman, P., Pinca, A., Spanevello, A., Resta, O., Musti, M., and Sterk, PJ.

--- For September, 2011 ---

1.)	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS. Cancer Immunol Immunother. 2011 Sep 13.

2.)	Mesothelioma in an individual following exposure to crocidolite-containing gaskets as a teenager. Dodson RF, Hammar SP, Poye LW. Int J Occup Environ Health. 2011 Jul-Sep;17(3):190-4.

3.)	Malignant pleural mesothelioma in Singapore. Yip CS, Koong H, Loo C, Fong K. Asian Pac J Cancer Prev. 2011;12(5):1155-9.

4.)	A retrospective study of chest pain in benign asbestos pleural disease Allen RK, Cramond T, Lennon D, Waterhouse M. Pain Med. 2011 Aug 11. doi: 10.1111/j.1526-4637.2011.01209.x.

5.)	Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, Musk B. Med J Aust. 2011 Sep 5;195(5):271-4.

6.)	Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S. Lung Cancer. 2011 Sep 2.

--- For July, 2011 ---

1.)	Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Raza A, Jacobson BA, Benoit A, Patel MR, Jay-Dixon J, Hiasa H, Ferguson DM, Kratzke RA.

2.)	New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D'Urso V, Grilli B, Botta M, Giordano A, Pentimalli F

3.)	Totoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding (hyperlink to this article) Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I.

4.)	Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS.

5.)	The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma . Erculj N, Kovac V, Hmeljak J, Dolzan V.

6.)	The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N.